REGENERON PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability
REGENERON PHARMACEUTICALS, INC. (REGN) reported Increase (Decrease) in Contract with Customer, Liability of $143.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $43.90M.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $99.60M, a 462.71% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$3.10M.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $76.60M, a 78.14% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$51.70M, a 122.70% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $227.80M, a 501.06% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $37.90M, a 16.98% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $32.40M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $143.50M 10-Q · filed 2026-07-30 | $140.40M derived: sum of 3 quarters · filed 2026-07-30 | $217.00M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $99.60M 10-Q · filed 2026-04-29 | $96.50M derived: sum of 2 quarters · filed 2026-04-29 | $173.10M derived: sum of 3 quarters · filed 2026-04-29 | $30.20M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $73.50M derived: sum of 2 quarters · filed 2026-02-04 | -$69.40M derived: sum of 3 quarters · filed 2026-07-30 | -$51.70M 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $76.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$66.30M derived: sum of 2 quarters · filed 2026-07-30 | -$48.60M 10-Q · filed 2025-10-28 | -$69.80M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | -$142.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$125.20M 10-Q · filed 2026-07-30 | -$146.40M derived: sum of 3 quarters · filed 2026-07-30 | -$103.40M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $17.70M 10-Q · filed 2026-04-29 | -$3.50M derived: sum of 2 quarters · filed 2026-04-29 | $39.50M derived: sum of 3 quarters · filed 2026-04-29 | $128.60M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | -$21.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $21.80M derived: sum of 2 quarters · filed 2026-02-04 | $110.90M derived: sum of 3 quarters · filed 2026-02-04 | $227.80M 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $43.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $132.10M derived: sum of 2 quarters · filed 2025-10-28 | $249.00M 10-Q · filed 2025-10-28 | $292.00M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $89.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $206.00M 10-Q · filed 2025-08-01 | $249.00M derived: sum of 3 quarters · filed 2026-02-04 | $294.30M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $116.90M 10-Q · filed 2025-04-29 | $159.90M derived: sum of 2 quarters · filed 2026-02-04 | $205.20M derived: sum of 3 quarters · filed 2026-02-04 | $190.70M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $43.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $88.30M derived: sum of 2 quarters · filed 2026-02-04 | $73.80M derived: sum of 3 quarters · filed 2026-02-04 | $37.90M 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $45.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $30.80M derived: sum of 2 quarters · filed 2024-10-31 | -$5.10M 10-Q · filed 2024-10-31 | -$64.70M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | -$14.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$50.40M 10-Q · filed 2024-08-01 | -$110.00M derived: sum of 3 quarters · filed 2025-02-05 | -$127.70M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | -$35.90M 10-Q · filed 2024-05-02 | -$95.50M derived: sum of 2 quarters · filed 2025-02-05 | -$113.20M derived: sum of 3 quarters · filed 2025-02-05 | -$13.00M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | -$59.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | -$77.30M derived: sum of 2 quarters · filed 2025-02-05 | $22.90M derived: sum of 3 quarters · filed 2025-02-05 | $32.40M 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | -$17.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $82.50M derived: sum of 2 quarters · filed 2023-11-02 | $92.00M 10-Q · filed 2023-11-02 | $43.00M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $100.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $109.70M 10-Q · filed 2023-08-03 | $60.70M derived: sum of 3 quarters · filed 2024-02-05 | $54.30M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $9.50M 10-Q · filed 2023-05-04 | -$39.50M derived: sum of 2 quarters · filed 2024-02-05 | -$45.90M derived: sum of 3 quarters · filed 2024-02-05 | $32.90M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | -$49.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | -$55.40M derived: sum of 2 quarters · filed 2024-02-05 | $23.40M derived: sum of 3 quarters · filed 2024-02-05 | -$120.20M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | -$6.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $72.40M derived: sum of 2 quarters · filed 2022-11-03 | -$71.20M 10-Q · filed 2022-11-03 | -$35.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $78.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$64.80M 10-Q · filed 2022-08-03 | -$29.00M derived: sum of 3 quarters · filed 2023-02-06 | $4.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | -$143.60M 10-Q · filed 2022-05-04 | -$107.80M derived: sum of 2 quarters · filed 2023-02-06 | -$74.40M derived: sum of 3 quarters · filed 2023-02-06 | -$69.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $35.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $69.20M derived: sum of 2 quarters · filed 2023-02-06 | $74.20M derived: sum of 3 quarters · filed 2023-02-06 | $148.10M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $33.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $38.40M derived: sum of 2 quarters · filed 2021-11-04 | $112.30M 10-Q · filed 2021-11-04 | $85.00M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $78.90M 10-Q · filed 2021-08-05 | $51.60M derived: sum of 3 quarters · filed 2022-02-07 | $88.60M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $73.90M 10-Q · filed 2021-05-06 | $46.60M derived: sum of 2 quarters · filed 2022-02-07 | $83.60M derived: sum of 3 quarters · filed 2022-02-07 | $132.30M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | -$27.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $9.70M derived: sum of 2 quarters · filed 2022-02-07 | $58.40M derived: sum of 3 quarters · filed 2022-02-07 | $139.50M 10-K · filed 2022-02-07 | $294.00M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $37.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $85.70M derived: sum of 2 quarters · filed 2020-11-05 | $166.80M 10-Q · filed 2020-11-05 | $375.80M 10-Q · filed 2019-11-05 | $152.90M derived: sum of 4 quarters · filed 2021-02-08 | |||
| 2019-06-30 | $48.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $129.80M 10-Q · filed 2020-08-05 | $401.10M 10-Q · filed 2019-08-06 | $115.90M derived: sum of 3 quarters · filed 2021-02-08 | $170.60M derived: sum of 4 quarters · filed 2021-02-08 | |||
| 2019-03-31 | $81.10M 10-Q · filed 2020-05-05 | $426.50M 10-Q · filed 2019-05-07 | $67.20M derived: sum of 2 quarters · filed 2021-02-08 | $121.90M derived: sum of 3 quarters · filed 2021-02-08 | $92.20M derived: sum of 4 quarters · filed 2021-02-08 | |||
| 2018-12-31 | -$13.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $40.80M derived: sum of 2 quarters · filed 2021-02-08 | $11.10M derived: sum of 3 quarters · filed 2021-02-08 | -$43.40M 10-K · filed 2021-02-08 | -$194.50M 10-K · filed 2019-02-07 | |||
| 2018-09-30 | $54.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $25.00M derived: sum of 2 quarters · filed 2019-11-05 | -$29.50M 10-Q · filed 2019-11-05 | -$29.46M 10-Q · filed 2018-11-06 | -$83.48M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | -$29.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$84.20M 10-Q · filed 2019-08-06 | -$84.24M 10-Q · filed 2018-08-02 | -$138.18M derived: sum of 3 quarters · filed 2020-02-07 | -$186.65M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | -$54.50M 10-Q · filed 2019-05-07 | -$108.48M derived: sum of 2 quarters · filed 2020-02-07 | -$156.94M derived: sum of 3 quarters · filed 2020-02-07 | |||||
| 2017-12-31 | -$53.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | -$102.44M derived: sum of 2 quarters · filed 2020-02-07 | -$113.10M 10-K · filed 2020-02-07 | |||||
| 2017-09-30 | -$48.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$59.12M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | -$10.65M 10-Q · filed 2018-08-02 | |||||||
| 2016-12-31 | $244.30M 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |